Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 21 September 2022, 19:00 HKT/SGT
Share:
    

Source: Malaysian Genomics Resource Centre Berhad
Malaysian Genomics, Rinani Genotec Sign LOI with Universiti Malaysia Sabah
Parties agree to collaborate on research in genetics, regenerative and alternative medicine

PETALING JAYA, Malaysia, Sept 21, 2022 - (ACN Newswire) - Leading genomics and biopharmaceutical specialist Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155) is pleased to report that the Group has signed a letter of intent (LOI) with the Faculty of Science and Natural Resources, Universiti Malaysia Sabah (UMS) and Rinani Genotec Sdn Bhd (Genotec) to collaborate on research and development (R&D) in genetics, and regenerative and alternative medicines.

Chairman of Malaysian Genomics, Datuk Seri Dr. Chen Chaw Min

Under the LOI, MGRC, which owns a high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, as well as Genotec, which specializes in biomedical treatments using stem cells, will assist in strengthening the teaching and research activities of the undergraduate programme at UMS' Faculty of Science and Natural Resources.

This cooperation will enable the exchange of research resources and ideas to enhance the quality of research at UMS, as well as create opportunities for students from the Faculty of Science and Natural Resources to serve their internship period at MGRC or Genotec.

Chairman of Malaysian Genomics, Datuk Seri Dr. Chen Chaw Min, said, "We are happy to assist UMS undergraduates in pursuing their R&D goals so that they have a better understanding of their field of study. This is also in support of the National Biotechnology Policy 2.0 launched recently focusing on agriculture and food security, healthcare and wellbeing, as well as industrial and the circular economy."

The Dean of the Faculty of Science and Natural Resources, UMS, Professor Dr. Jualang Azlan Gansau said, "UMS is actively engaging in research as well as teaching activities and the involvement of industry is crucial in ensuring the relevance of such activities conducted at the University."

The signing of the LOI followed UMS' visit to MGRC's Biosafety Level 2 cGMP (Current Good Manufacturing Practice)-certified laboratory, which is used for the production of cell therapies, including CAR T-cell therapies for various cancers.

Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/


Topic: Press release summary
Source: Malaysian Genomics Resource Centre Berhad

Sectors: Daily News, BioTech, Healthcare & Pharm, Local Biz
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Malaysian Genomics Resource Centre Berhad
Nov 23, 2022 17:30 HKT/SGT
Malaysian Genomics Sees Rise in Profit Margins for 1Q
Oct 26, 2022 19:00 HKT/SGT
Malaysian Genomics Signs Strategic Collaboration Agreement for Expansion in the UAE
Oct 12, 2022 13:00 HKT/SGT
Malaysian Genomics Signs Agreement with National Institutes of Health to Explore Research Opportunities
Sept 23, 2022 14:00 HKT/SGT
Malaysian Genomics Grows Presence in Thailand
Aug 30, 2022 14:00 HKT/SGT
Malaysian Genomics Reports RM28.36 Million Full-Year Revenue
Aug 29, 2022 14:00 HKT/SGT
Malaysian Genomics Signs MoU with Ajlan to explore distribution of biopharmaceutical and genetic screening services in MENA region
Aug 18, 2022 18:00 HKT/SGT
Malaysian Genomics Explores Strategic Partnership with MAHSA Health through MoU
July 20, 2022 13:30 HKT/SGT
UCrest Partners with Malaysian Genomics to Digitalize Genome Services Worldwide
July 15, 2022 14:10 HKT/SGT
Malaysian Genomics Appoints New Chairman
July 13, 2022 15:00 HKT/SGT
Malaysian Genomics Forms Partnership for Expansion in Saudi Arabia
More news >>
 News Alerts
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: